Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma

Cancer

Volumn 100, Issue 11, 2004, Pages 2355-2361

  Shirao, Kuniaki ^a   Ohtsu, Atsushi ^b   Takada, Hideho ^c   Mitachi, Yasushi ^d   Hirakawa, Kosei ^e   Horikoshi, Noboru ^f   Okamura, Takeshi ^g   Hirata, Koichi ^h   Saitoh, Soh ⁱ   Isomoto, Hiroharu ^j   Satoh, Atsushi ^k  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c KANSAI MEDICAL UNIVERSITY   (Japan)

^d Sendai Koseikai Hospital   (Japan)

^e OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f CANCER INSTITUTE HOSPITAL   (Japan)

^g NATIONAL KYUSHU CANCER CENTER   (Japan)

^h SAPPORO MEDICAL UNIVERSITY   (Japan)

ⁱ AOMORI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^j KURUME UNIVERSITY MEDICAL CENTER   (Japan)

^k SHOWA UNIVERSITY   (Japan)

more..

Author keywords

5 fluorouracil derivative; Colorectal carcinoma; Oral fluoropyrimidine; Phase II study; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIARRHEA; DRUG FATALITY; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MALAISE; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PIGMENTATION; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; PYRIDINES; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME;

EID: 2442674385     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20277     Document Type: Article

References (34)

1. Scheithauer W, Rosen H, Koreck GV, Sebesta C, Depisci, D. Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ. 1993;306:752-755.
2. Douillard JY, Cunningham D, Roth AD, et al. Iripotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatis colorectal cancer: a multicentere randomized trial. Lancet. 2000;355:1041-1047.
3. Douillard JY, Sobrero A, Carnaghi C, et al. Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy. Ann Oncol. 2003;14 Suppl 2:117-1112.
4. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000;343:905-914.
5. Sargent D, Niedzwiecki D, O'Connell MJ, Schilsky RL. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med. 2001;345:144-145.
6. Goldberg RM, Morton RF, Sargent DJ, et al. N9741: oxaliplatin (oral) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oral + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a G? Intergroup study [abstract]. Proc Am Soc Clin Oncol. 2002;21:128a.
7. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist. 2002;7:288-323.
8. Douillard JY, Hoff PM, Skillings JR, et al. Multicenter Phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2002;20:3605-3616.
9. Carmichael J, Popiela T, Radstone D, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2002;20:3617-3627.
10. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous 5-fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer. Results of a randomized Phase III study. J Clin Oncol. 2001;19:2282-2292.
11. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III study. J Clin Oncol. 2001;19:4097-4106.
12. DeMario MD, Ratain MJ. Oral chemotherapy: rationale and future directions. J Clin Oncol. 1998;16:2557-2567.
13. Sugimachi K, Maehara Y, Horikoshi N, et al. An early Phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology. 1999;57:202-210.
14. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late Phase II study of novel oral fluoropyrimidine anticancer drugs S-I (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 1998;34:1715-1720.
15. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology. 2000;58:191-197.
16. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B. [Late Phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Cancer Working Group)]. Gan To Kagaku Ryoho. 2001;28:1381-1390.
17. Shirasaka T, Nakano K, Takechi T, et al. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. 1993;56:2602-2606.
18. Tatsumi K, Fukushima M, Shirasaka T, Fujii S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res. 1987;78:748-755.
19. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 1993;53:4004-4009.
20. Takechi T, Nakano K, Uchida J, et al. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rat. Cancer Chemother Pharmacol. 1997;39:205-211.
21. Fukushima M, Satake H, Uchida J, et al. Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol. 1998;13:693-698.
22. Taguchi T, Inuyama Y, Kanamaru R, et al. [Phase I study of S-1. S-1 Study Group]. Gan To Kagaku Ryoho. 1997;24:2253-2264.
23. Hirata K, Horikoshi N, Aiba K, et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res. 1999;5:2000-2005.
24. Ohtsu A, Baba H, Sakata Y, et al. Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer. 2000;83:141-145.
25. Japanese Society for Cancer of Colon and Rectum. Japanese classification of colorectal carcinoma (1st English edition). Tokyo: Kanehara Syuppan, 1997:77-80.
26. Japan Society for Cancer Therapy. Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther. 1993;28:101-130.
27. Kawahara M, Furuse K, Segawa Y, et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer. 2001;85:939-943.
28. Saeki T, Takashima S, Sano M, et al. [A late Phase II clinical study of S-1 in patients with progressed, refractory breast cancer]. Gan To Kagaku Ryoho. In press.
29. Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol. 1998;16:3537-3541.
30. Diasio RB. Can eniluracil improve 5-fluorouracil therapy? Clin Colorectal Cancer. 2002;2:53.
31. Borner MM, Schoffski P, de Wit R, et al. Patients preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer. 2002;38:349-358.
32. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110-115.
33. Chollet P, Schoffski P, Weigang-Kohler K, et al. Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer. 2003;39:1264-1270.
34. Van den Brande J, Schoffski P, Schellens JH, et al. EORTC Early Clinical Studies Group early Phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer. 2003;88:648-653.